Rep. April McClain Delaney Sells IDEXX Laboratories, Inc. (NASDAQ:IDXX) Stock

Representative April McClain Delaney (D-Maryland) recently sold shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX). In a filing disclosed on February 02nd, the Representative disclosed that they had sold between $1,001 and $15,000 in IDEXX Laboratories stock on January 13th.

Representative April McClain Delaney also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of PTC (NASDAQ:PTC) on 1/30/2026.
• Sold $1,001 – $15,000 in shares of Wabtec (NYSE:WAB) on 1/30/2026.
• Sold $1,001 – $15,000 in shares of Trimble (NASDAQ:TRMB) on 1/29/2026.
• Sold $1,001 – $15,000 in shares of Bio-Techne (NASDAQ:TECH) on 1/28/2026.
• Sold $1,001 – $15,000 in shares of BJ’s Wholesale Club (NYSE:BJ) on 1/28/2026.
• Sold $1,001 – $15,000 in shares of Trimble (NASDAQ:TRMB) on 1/28/2026.
• Purchased $1,001 – $15,000 in shares of Labcorp (NYSE:LH) on 1/28/2026.
• Sold $1,001 – $15,000 in shares of PTC (NASDAQ:PTC) on 1/23/2026.
• Sold $1,001 – $15,000 in shares of Somnigroup International (NYSE:SGI) on 1/22/2026.
• Sold $1,001 – $15,000 in shares of Wabtec (NYSE:WAB) on 1/22/2026.

IDEXX Laboratories Stock Performance

Shares of NASDAQ:IDXX opened at $632.56 on Wednesday. The firm’s 50 day simple moving average is $700.41 and its 200-day simple moving average is $663.48. The company has a debt-to-equity ratio of 0.23, a quick ratio of 0.87 and a current ratio of 1.23. IDEXX Laboratories, Inc. has a one year low of $356.14 and a one year high of $769.98. The firm has a market cap of $50.51 billion, a PE ratio of 48.40, a price-to-earnings-growth ratio of 3.41 and a beta of 1.67.

IDEXX Laboratories (NASDAQ:IDXX) last announced its quarterly earnings data on Monday, February 2nd. The company reported $3.08 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.93 by $0.15. The company had revenue of $1.09 billion for the quarter, compared to analysts’ expectations of $1.07 billion. IDEXX Laboratories had a return on equity of 69.78% and a net margin of 24.62%.IDEXX Laboratories’s revenue was up 14.3% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $2.53 earnings per share. IDEXX Laboratories has set its FY 2026 guidance at 14.290-14.800 EPS. As a group, equities analysts predict that IDEXX Laboratories, Inc. will post 11.93 EPS for the current year.

Institutional Investors Weigh In On IDEXX Laboratories

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Virtus Advisers LLC purchased a new position in shares of IDEXX Laboratories in the 3rd quarter valued at approximately $26,000. Park Place Capital Corp acquired a new position in IDEXX Laboratories during the 4th quarter valued at approximately $29,000. WealthCollab LLC purchased a new position in shares of IDEXX Laboratories in the second quarter worth $30,000. J.Safra Asset Management Corp purchased a new position in shares of IDEXX Laboratories in the third quarter worth $31,000. Finally, Armstrong Advisory Group Inc. lifted its stake in shares of IDEXX Laboratories by 55.9% during the third quarter. Armstrong Advisory Group Inc. now owns 53 shares of the company’s stock worth $34,000 after buying an additional 19 shares during the period. 87.84% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In related news, EVP Nimrata Hunt sold 9,425 shares of the firm’s stock in a transaction on Friday, November 7th. The stock was sold at an average price of $703.34, for a total value of $6,628,979.50. Following the completion of the transaction, the executive vice president owned 21,149 shares in the company, valued at $14,874,937.66. This trade represents a 30.83% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. 0.98% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

IDXX has been the topic of several recent research reports. UBS Group dropped their target price on shares of IDEXX Laboratories from $750.00 to $730.00 and set a “neutral” rating on the stock in a report on Tuesday. Stifel Nicolaus set a $775.00 price objective on shares of IDEXX Laboratories in a research note on Monday, November 3rd. BTIG Research reduced their price objective on shares of IDEXX Laboratories from $830.00 to $800.00 and set a “buy” rating for the company in a research note on Tuesday. Wall Street Zen lowered IDEXX Laboratories from a “strong-buy” rating to a “buy” rating in a report on Saturday, January 17th. Finally, Barclays assumed coverage on IDEXX Laboratories in a report on Monday, December 8th. They issued an “overweight” rating and a $850.00 price target on the stock. Seven research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $783.33.

Key IDEXX Laboratories News

Here are the key news stories impacting IDEXX Laboratories this week:

• Positive Sentiment: IDXX beat Q4 expectations — reported $3.08 EPS vs. $2.93 consensus and $1.091B revenue, with margins improving and double-digit year-over-year revenue growth; this underscores resilient demand in core diagnostics. Business Wire: IDEXX Announces Fourth Quarter and Full-Year 2025 Results
• Positive Sentiment: Companion Animal Group (CAG) and Water businesses showed strong growth (CAG ~15% reported; Water ~12%), and management highlighted innovation and higher tests per visit as growth drivers — supporting mid/long-term revenue expansion. Seeking Alpha: Idexx targets $4.632B–$4.720B revenue for 2026
• Neutral Sentiment: Management issued FY2026 guidance (EPS range 14.290–14.800, revenue $4.6B–$4.7B); the EPS range is roughly in line with Street expectations while revenue guidance is at/just below consensus, leaving room for interpretation. Reuters: IDEXX forecasts 2026 revenue, profit above estimates
• Neutral Sentiment: Full earnings call transcripts and slide deck are available; management commentary reiterates innovation-led growth and clinic testing intensity as key assumptions — useful for modeling but not immediately market-moving. MSN: IDEXX Q4 2025 earnings call transcript
• Negative Sentiment: Some analysts trimmed forecasts after the print and guidance, signaling lowered near-term expectations and prompting downward pressure on the stock. Benzinga: Analysts Cut Their Forecasts Following Q4 Results
• Negative Sentiment: Market reaction focused on the outlook: despite a beat, commentary and the revenue range prompted investors to pare positions, with coverage noting shares trimmed on the guidance nuance. MSN: IDEXX tops revenue forecasts, shares edge lower on outlook

About Representative McClain Delaney

April McClain-Delaney (Democratic Party) is a member of the U.S. House, representing Maryland’s 6th Congressional District. She assumed office on January 3, 2025. Her current term ends on January 3, 2027.

McClain-Delaney (Democratic Party) is running for re-election to the U.S. House to represent Maryland’s 6th Congressional District. She declared candidacy for the 2026 election.

April McClain-Delaney grew up in Buhl, Idaho, where her father was a potato farmer. She obtained her bachelor’s degree in communications from Northwestern University in 1986 and her law degree from Georgetown Law Center in 1989. McClain-Delaney worked in communications law, first with the satellite firm Orion Network Systems and later as the Washington director for Common Sense Media, a nonprofit focused on technology and children. In 2022, McClain-Delaney joined the U.S. Department of Commerce under President Joe Biden (D) as deputy assistant secretary for communications and information. McClain-Delaney served on the board of the Georgetown University Law Center, the International Center for Research on Women, and the Northwestern University School of Communications.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.